Adverse reactions associated with immune checkpoint inhibitors and bevacizumab: A pharmacovigilance analysis
暂无分享,去创建一个
Q. Cheng | Jian Zhang | P. Luo | Ai-min Jiang | Anqi Lin | Chaozheng Zhou | Zaoqu Liu | T. Gu
[1] Jian Zhang,et al. MOAHIT: a web tool for visualizing tumor multi-omics data with human anatomy heatmaps , 2022, bioRxiv.
[2] Shing M. Lee,et al. Sex Differences in Risk of Severe Adverse Events in Patients Receiving Immunotherapy, Targeted Therapy, or Chemotherapy in Cancer Clinical Trials , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] R. Murray,et al. Characterisation of the onset and severity of adrenal and thyroid dysfunction associated with CTLA4-related hypophysitis. , 2021, European journal of endocrinology.
[4] E. Ehrenpreis,et al. Bevacizumab and gastrointestinal perforations: a review from the FDA Adverse Event Reporting System (FAERS) database , 2021, Alimentary pharmacology & therapeutics.
[5] Jian Zhang,et al. Effect of NCOR1 Mutations on Immune Microenvironment and Efficacy of Immune Checkpoint Inhibitors in Patient with Bladder Cancer , 2021, Frontiers in Immunology.
[6] K. Poppe. Management of endocrine disease: Thyroid and Female Infertility:More Questions than Answers?! , 2021, European journal of endocrinology.
[7] Chiun Hsu,et al. Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab , 2021, Therapeutic advances in medical oncology.
[8] Shijun Kang,et al. ZFHX3 mutation as a protective biomarker for immune checkpoint blockade in non-small cell lung cancer , 2020, Cancer Immunology, Immunotherapy.
[9] G. Valabrega,et al. Immuno-Metabolism and Microenvironment in Cancer: Key Players for Immunotherapy , 2020, International journal of molecular sciences.
[10] Jian Zhang,et al. Crosstalk between the MSI status and tumor microenvironment in colorectal cancer. , 2020 .
[11] Yulei N. Wang,et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. , 2020, The New England journal of medicine.
[12] A. Hérault,et al. Anti-VEGF Treatment Enhances CD8+ T-cell Antitumor Activity by Amplifying Hypoxia , 2020, Cancer Immunology Research.
[13] O. Chinot,et al. Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook. , 2020, Cancer treatment reviews.
[14] C. López-Camarillo,et al. Contribution of Angiogenesis to Inflammation and Cancer , 2019, Front. Oncol..
[15] Jin-fang Xu,et al. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system , 2019, Journal of Immunotherapy for Cancer.
[16] B. Liu,et al. Randomised efficacy and safety results for atezolizumab (Atezo) + bevacizumab (Bev) in patients (pts) with previously untreated, unresectable hepatocellular carcinoma (HCC) , 2019, Annals of Oncology.
[17] Hui Meng,et al. Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations , 2019, Molecular Cancer.
[18] D. de Ruysscher,et al. Current status of immune checkpoint inhibition in early stage NSCLC. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[19] Y. Tomita,et al. Protective effect of bevacizumab on chemotherapy-related acute exacerbation of interstitial lung disease in patients with advanced non-squamous non-small cell lung cancer , 2019, BMC Pulmonary Medicine.
[20] Anping Li,et al. Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment , 2019, Molecular Cancer.
[21] Yun-tao Jia,et al. Adverse Event Profiles of Anti-CTLA-4 and Anti-PD-1 Monoclonal Antibodies Alone or in Combination: Analysis of Spontaneous Reports Submitted to FAERS , 2019, Clinical Drug Investigation.
[22] Joe Y. Chang,et al. Time to abandon single-site irradiation for inducing abscopal effects , 2018, Nature Reviews Clinical Oncology.
[23] S. Gettinger,et al. Nivolumab Plus Erlotinib in Patients With EGFR‐Mutant Advanced NSCLC , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[24] M. Kudo,et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. , 2018, The Lancet. Oncology.
[25] Federico Cappuzzo,et al. Atezolizumab for First‐Line Treatment of Metastatic Nonsquamous NSCLC , 2018, The New England journal of medicine.
[26] Dai Fukumura,et al. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges , 2018, Nature Reviews Clinical Oncology.
[27] P. Hegde,et al. Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics. , 2017, Seminars in cancer biology.
[28] W. Barry,et al. Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis , 2017, JAMA oncology.
[29] D. Kroetz,et al. Bevacizumab‐induced hypertension: Clinical presentation and molecular understanding , 2017, Pharmacology & therapeutics.
[30] N. Girard,et al. Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients , 2017, European Respiratory Journal.
[31] F. Hodi,et al. Monitoring immune-checkpoint blockade: response evaluation and biomarker development , 2017, Nature Reviews Clinical Oncology.
[32] M. Kudo,et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial , 2017, The Lancet.
[33] R. Ronca,et al. Tumor angiogenesis revisited: Regulators and clinical implications , 2017, Medicinal research reviews.
[34] T. Choueiri,et al. Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients , 2017, Cancer Immunology Research.
[35] K. Chester,et al. Ipilimumab and Bevacizumab in Glioblastoma. , 2016, Clinical oncology (Royal College of Radiologists (Great Britain)).
[36] F. Hodi,et al. PD-1 Inhibitor–Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course , 2016, Clinical Cancer Research.
[37] D. Lynch,et al. Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. , 2016, American journal of respiratory and critical care medicine.
[38] Matthieu Texier,et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination , 2016, Nature Reviews Clinical Oncology.
[39] R. Pazdur,et al. FDA subset analysis of the safety of nivolumab in elderly patients with advanced cancers. , 2016 .
[40] Pei San Ang,et al. Data mining spontaneous adverse drug event reports for safety signals in Singapore – a comparison of three different disproportionality measures , 2016, Expert opinion on drug safety.
[41] J. Soria,et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. , 2016, European journal of cancer.
[42] A. Snyder,et al. Acquired resistance to immunotherapy and future challenges , 2016, Nature Reviews Cancer.
[43] J. Bedő,et al. Spleen Volume Variation in Patients with Locally Advanced Non-Small Cell Lung Cancer Receiving Platinum-Based Chemo-Radiotherapy , 2015, PloS one.
[44] M. Antoine,et al. Crizotinib Associated with Ground-Glass Opacity Predominant Pattern Interstitial Lung Disease: A Retrospective Observational Cohort Study with a Systematic Literature Review , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[45] R. Jain,et al. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. , 2014, Cancer cell.
[46] Yongfang Hou,et al. A comparison of disproportionality analysis methods in national adverse drug reaction databases of China , 2014, Expert opinion on drug safety.
[47] A. D. Van den Abbeele,et al. Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma , 2014, Cancer Immunology Research.
[48] A. Millar,et al. Vascular Endothelial Growth Factor in Acute Lung Injury and Acute Respiratory Distress Syndrome , 2013, Respiration.
[49] M. Shibuya. VEGFR and type-V RTK activation and signaling. , 2013, Cold Spring Harbor perspectives in biology.
[50] F. Guadagni,et al. Effects of conventional therapeutic interventions on the number and function of regulatory T cells , 2013, Oncoimmunology.
[51] F. Sweep,et al. Role of Endogenous Vascular Endothelial Growth Factor in Endothelium-Dependent Vasodilation in Humans , 2013, Hypertension.
[52] M. Joerger,et al. Interstitial Pneumonitis after Treatment with Pemetrexed: A Rare Event? , 2012, Chemotherapy.
[53] R. Gray,et al. Sex Differences in Outcome with Bevacizumab Therapy: Analysis of Patients with Advanced-Stage Non-small Cell Lung Cancer Treated with or without Bevacizumab in Combination with Paclitaxel and Carboplatin in the Eastern Cooperative Oncology Group Trial 4599 , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[54] H. Wakelee,et al. Survival Differences by Sex for Patients with Advanced Non-small Cell Lung Cancer on Eastern Cooperative Oncology Group Trial 1594 , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[55] E. Tartour,et al. Immunomodulatory Activity of VEGF in Cancer. , 2017, International review of cell and molecular biology.